Trends of Fixed-Dose Combination Antibiotic Consumption in Hospitals in China: Analysis of Data from the Center for Antibacterial Surveillance, 2013-2019

Overview

Journal Antibiotics (Basel)

Specialty Pharmacology

Date 2022 Jul 27

PMID 35884211

Authors

Haishaerjiang Wushouer

Lin Hu

Yue Zhou

Yaoyao Yang

Kexin Du

Yanping Deng

Qing Yan

Xiaoqiang Yang

Zhidong Chen

Bo Zheng

Xiaodong Guan

Luwen Shi

Affiliations

Soon will be listed here.

Abstract

Background: Fixed-dose combination (FDC) antibiotics can be clinically inappropriate and are concerning with regards to antimicrobial resistance, with little usage data available in low- and middle-income countries. Methods: Based on retrospective data from the Center for Antibacterial Surveillance, we investigated the consumption of FDC antibiotics in hospital inpatient settings in China from 1 January 2013 to 31 December 2019. The metric for assessing antibiotic consumption was the number of daily defined doses per 100 bed days (DDD/100BDs). FDC antibiotics were classified according to their composition and the Access, Watch, Reserve (AWaRe) classification of the World Health Organization. Results: A total of 24 FDC antibiotics were identified, the consumption of which increased sharply from 8.5 DDD/100BDs in 2013 to 10.2 DDD/100BDs in 2019 (p < 0.05) despite the reduction in the total antibiotic consumption in these hospitals. The increase was mainly driven by FDC antibiotics in the Not Recommended group of the AWaRe classification, whose consumption accounted for 63.0% (6.4 DDD/100BDs) of the overall FDC antibiotic consumption in 2019, while the consumption of FDC antibiotics in the Access group only accounted for 13.5% (1.4 DDD/100BDs). Conclusion: FDC antibiotic consumption significantly increased during the study period and accounted for a substantial proportion of all systemic antibiotic usage in hospitals in China. FDC antibiotics in the Not Recommended group were most frequently consumed, which raises concerns about the appropriateness of FDC antibiotic use.

Citing Articles

Unveiling the drivers of vancomycin-resistant enterococcus in China: A comprehensive ecological study.

Wang J, Li X, Du X, Jia H, Chen H, Wu J Infect Med (Beijing). 2025; 4(1):100159.

PMID: 39911600 PMC: 11794159. DOI: 10.1016/j.imj.2024.100159.

Prescribing Trends of Fixed-Dose Combination Antibiotics Not Recommended by the WHO (FNRs) for ICU Patients in Six Major Areas of China During a Seven-Year Period.

Zhou L, Zhao Y, Zhu J, Liu J, Liang G, Yang Y Drug Des Devel Ther. 2024; 18:5781-5791.

PMID: 39664964 PMC: 11632048. DOI: 10.2147/DDDT.S493980.

Fixed-Dose Combination Formulations in Solid Oral Drug Therapy: Advantages, Limitations, and Design Features.

Wilkins C, Hamman H, Hamman J, Steenekamp J Pharmaceutics. 2024; 16(2).

PMID: 38399239 PMC: 10892518. DOI: 10.3390/pharmaceutics16020178.

Regulatory enforcement of the marketing of fixed-dose combinations in India: a case study of systemic antibiotics.

Brhlikova P, Mehta A, McGettigan P, Pollock A, Roderick P, Hasan Farooqui H J Pharm Policy Pract. 2023; 16(1):139.

PMID: 37950272 PMC: 10636890. DOI: 10.1186/s40545-023-00644-y.

References

Connor J, Rafter N, Rodgers A . Do fixed-dose combination pills or unit-of-use packaging improve adherence? A systematic review. Bull World Health Organ. 2005; 82(12):935-9. PMC: 2623099. DOI: /S0042-96862004001200010. View

Poudel A, Ibrahim M, Mishra P, Palaian S . Assessment of the availability and rationality of unregistered fixed dose drug combinations in Nepal: a multicenter cross-sectional study. Glob Health Res Policy. 2017; 2:14. PMC: 5683238. DOI: 10.1186/s41256-017-0033-z. View

McGettigan P, Roderick P, Kadam A, Pollock A . Threats to global antimicrobial resistance control: Centrally approved and unapproved antibiotic formulations sold in India. Br J Clin Pharmacol. 2018; 85(1):59-70. PMC: 6303201. DOI: 10.1111/bcp.13503. View

Bortone B, Jackson C, Hsia Y, Bielicki J, Magrini N, Sharland M . High global consumption of potentially inappropriate fixed dose combination antibiotics: Analysis of data from 75 countries. PLoS One. 2021; 16(1):e0241899. PMC: 7817037. DOI: 10.1371/journal.pone.0241899. View

Zhao H, Wei L, Li H, Zhang M, Cao B, Bian J . Appropriateness of antibiotic prescriptions in ambulatory care in China: a nationwide descriptive database study. Lancet Infect Dis. 2021; 21(6):847-857. DOI: 10.1016/S1473-3099(20)30596-X. View

Bush K, Bradford P . Epidemiology of β-Lactamase-Producing Pathogens. Clin Microbiol Rev. 2020; 33(2). PMC: 7048014. DOI: 10.1128/CMR.00047-19. View

Wang L, Chen Y, Han R, Huang Z, Zhang X, Hu F . Sulbactam Enhances in vitro Activity of β-Lactam Antibiotics Against . Infect Drug Resist. 2021; 14:3971-3977. PMC: 8487265. DOI: 10.2147/IDR.S332160. View

Cassini A, Hogberg L, Plachouras D, Quattrocchi A, Hoxha A, Simonsen G . Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis. Lancet Infect Dis. 2018; 19(1):56-66. PMC: 6300481. DOI: 10.1016/S1473-3099(18)30605-4. View

Li H, Yan S, Li D, Gong Y, Lu Z, Yin X . Trends and patterns of outpatient and inpatient antibiotic use in China's hospitals: data from the Center for Antibacterial Surveillance, 2012-16. J Antimicrob Chemother. 2019; 74(6):1731-1740. DOI: 10.1093/jac/dkz062. View

10.

Wareham D, Abdul Momin M, Phee L, Hornsey M, Standing J . Cefepime/sulbactam as an enhanced antimicrobial combination therapy for the treatment of MDR Gram-negative infections. J Antimicrob Chemother. 2019; 75(1):135-139. DOI: 10.1093/jac/dkz420. View

11.

Rodriguez-Bano J, Gutierrez-Gutierrez B, Machuca I, Pascual A . Treatment of Infections Caused by Extended-Spectrum-Beta-Lactamase-, AmpC-, and Carbapenemase-Producing Enterobacteriaceae. Clin Microbiol Rev. 2018; 31(2). PMC: 5967687. DOI: 10.1128/CMR.00079-17. View

12.

Ahmad A, Khan M, Balkrishnan R . Fixed-dose combination antibiotics in India: global perspectives. Lancet Glob Health. 2016; 4(8):e521. DOI: 10.1016/S2214-109X(16)30093-6. View

13.

Van Boeckel T, Gandra S, Ashok A, Caudron Q, Grenfell B, Levin S . Global antibiotic consumption 2000 to 2010: an analysis of national pharmaceutical sales data. Lancet Infect Dis. 2014; 14(8):742-750. DOI: 10.1016/S1473-3099(14)70780-7. View

14.

Harries A, Lawn S, Suthar A, Granich R . Benefits of combined preventive therapy with co-trimoxazole and isoniazid in adults living with HIV: time to consider a fixed-dose, single tablet coformulation. Lancet Infect Dis. 2015; 15(12):1492-6. DOI: 10.1016/S1473-3099(15)00242-X. View

15.

Xiao S, Zhuo C, Zhuo C . Activity of Various Sulbactam Compounds and Piperacillin/Tazobactam against Clinical Isolates of Different Gram-Negative Bacteria. Comput Math Methods Med. 2021; 2021:1175379. PMC: 8639252. DOI: 10.1155/2021/1175379. View

16.

Wirtz V, Mol P, Verdijk J, Vander Stichele R, Taxis K . Use of antibacterial fixed-dose combinations in the private sector in eight Latin American Countries between 1999 and 2009. Trop Med Int Health. 2013; 18(4):416-25. DOI: 10.1111/tmi.12068. View

17.

Boyd N, Teng C, Frei C . Brief Overview of Approaches and Challenges in New Antibiotic Development: A Focus On Drug Repurposing. Front Cell Infect Microbiol. 2021; 11:684515. PMC: 8165386. DOI: 10.3389/fcimb.2021.684515. View

18.

Klein E, Milkowska-Shibata M, Tseng K, Sharland M, Gandra S, Pulcini C . Assessment of WHO antibiotic consumption and access targets in 76 countries, 2000-15: an analysis of pharmaceutical sales data. Lancet Infect Dis. 2020; 21(1):107-115. DOI: 10.1016/S1473-3099(20)30332-7. View

19.

Shapiro A . Kinetics of Sulbactam Hydrolysis by β-Lactamases, and Kinetics of β-Lactamase Inhibition by Sulbactam. Antimicrob Agents Chemother. 2017; 61(12). PMC: 5700308. DOI: 10.1128/AAC.01612-17. View

20.

DiMasi J, Grabowski H, Hansen R . Innovation in the pharmaceutical industry: New estimates of R&D costs. J Health Econ. 2016; 47:20-33. DOI: 10.1016/j.jhealeco.2016.01.012. View